A Phase 1/2 interventional study of Oral C13 in Disorder of the Urea Cycle, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Status unknown at 1 site in Belgium. Open to participants aged 2 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-07-31.
Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Phase 1/2, Interventional, and Diagnostic
The aim of this pilot study is to evaluate the validity and reproducibility of a functional test "Test C13" ureogenesis to measure in vivo, using the methodology Laboratory of Metabolic Diseases of "Cliniques Universitaires Saint-Luc"
Cliniques universitaires Saint-Luc- Université Catholique de Louvain is the lead sponsor of 342 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The dose of sodium \[1-13C\] acetate is calculated according to patient weight (27mg/kg) or (0.33 mmol / kg).
Drug: Oral C13
Ingestion of C13 and follow up of the ureogenesis
Subject with a disorder of the urea cycle
Time frame: Day 1
This study is status unknown, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain